Sector
TradingOpen
₹19.25Prev. Close
₹19.25Turnover(Lac.)
₹1.32Day's High
₹19.25Day's Low
₹19.2552 Week's High
₹32.3652 Week's Low
₹13Book Value
₹8.24Face Value
₹10Mkt Cap (₹ Cr.)
28.51P/E
0EPS
0Divi. Yield
026 Aug 2024
12:00 AM
AGM
Announcement Date: 26 Aug, 2024
2 Nov 2024
12:00 AM
Board Meeting
Agenda : Audited Result
29 Sep 2023
12:00 AM
EGM
2 Sep 2023
12:00 AM
BookCloser
| Y/e 31 Mar( In .Cr) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
|---|---|---|---|---|
Equity Capital | 14.81 | 14.81 | 14.81 | 14.81 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | -2.47 | -2.22 | -1.51 | -3.01 |
Net Worth | 12.34 | 12.59 | 13.3 | 11.8 |
Minority Interest |
| Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Revenue | 0.01 | 1.43 | 0.61 | 1.28 |
yoy growth (%) | -99.09 | 132.17 | -51.85 | -65.33 |
Raw materials | 0 | -0.22 | -0.06 | -1.24 |
As % of sales | 14.85 | 15.7 | 10.39 | 97.04 |
Employee costs | -0.33 | -1.25 | -0.87 | -0.17 |
| Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Profit before tax | -0.76 | -1.89 | -1.02 | -0.31 |
Depreciation | 0 | -0.01 | 0 | 0 |
Tax paid | 0 | 0 | 0 | 0 |
Working capital | -0.39 | 0.23 | 0.97 | -0.22 |
Other operating items |
| Y/e 31 Mar | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | -99.09 | 132.17 | -51.85 | -65.33 |
Op profit growth | -55.44 | 99.89 | 205.88 | 893.01 |
EBIT growth | -59.27 | 85.03 | 219.51 | -2,313.54 |
Net profit growth | -59.27 | 85.03 | 219.51 | -2,313.54 |
| Particulars (Rupees in Crores.) | Mar-2021 | Mar-2020 | Mar-2019 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|---|
Gross Sales | 0.01 | 1.43 | 2.01 | 0.62 | 1.28 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 0.01 | 1.43 | 2.01 | 0.62 | 1.28 |
Other Operating Income | 0 | 0 | 0 | 0 | 0 |
Other Income | 0.15 | 0.16 | 0.11 | 0.03 | 0.01 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
|---|---|---|---|---|---|---|---|
Adani Enterprises Ltd ADANIENT | 2,229.65 | 92.21 | 2,51,905.72 | 627.99 | 0.06 | 6,586.92 | 189.95 |
Aegis Logistics Ltd AEGISLOG | 800.05 | 59.64 | 28,094.04 | 72.16 | 0.81 | 658.28 | 71.38 |
Cello World Ltd CELLO | 744.85 | 228.87 | 16,733.15 | 23.01 | 0.19 | 249.83 | 64.86 |
Redington Ltd REDINGTON | 194.7 | 13.76 | 14,970.98 | 618.08 | 3.24 | 12,384.69 | 50.08 |
MMTC Ltd MMTC | 74.32 | 84.71 | 11,055 | 38.16 | 0 | 1.56 | 9.58 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Chairman & Wholetime Director
K Krishnam Raju
Independent Director
B Suryaprakash Rao
Whole Time Director & CFO
K.N.V Narendra Kumar
Independent Director
Aakanksha
Independent Director
Ramamohan Reddy Yarragudi
Independent Director
A.S.S.V.Srinivas
Company Sec. & Compli. Officer
Deepa Dudani
Tel: -
Website: -
Email: -
Tel: -
Website: -
Email: -
Reports by Samsrita Labs Ltd
Summary
Samsrita Labs Limited (Formerly known Dr Habeebullah Life Sciences Limited) was incorporated on January 25, 1996. The Company name was changed from Dr Habeebullah Life Sciences Limited to Samsrita Labs Limited on October 13, 2022. The Company, initially focused on three different verticals called, Stem cell related Hospitals, Molecular Diagnostics and R&D in New Drug Discovery but due to other reasons, aimed to shifting into Bio-pharma activities like Trading, Exports & Imports, manufacturing of Bulk drugs, APIs, Specialty drugs, R&D etc through joint ventures or associations or mergers or by its own. The Company is engaged into the business of research & experimental development on natural sciences and engineering, including bio pharma and hospital services also.In 2017, the Company changed its Main Objects clauses by venturing into the business of Bio-Pharma and also entered the following areas like New Drug Discovery including New Molecular Entity (NME - Pro Drug); Clinical Research Organization (CRO) related activities; Stem Cell - Lab, Research and Therapy; Research and Development in Bio-technology; Consultancy Division and Pharmacy; Academic Services like Courses / Lectures / Seminars on Biotechnology, Pharma, Stem Cell Research and therapy, Clinical Research and animal studies etc.; Nutraceuticals product development; Trading, exporting and importing of medicinal drugs, chemicals, re-agents etc.In 2016-17, the Company entered into a Collaborative Agreement with Krisan
Read More
What is the Samsrita Labs Ltd share price today?
The Samsrita Labs Ltd shares price on BOMBAY STOCK EXCHANGE (BSE) is ₹19.25 today.
What is the Market Cap of Samsrita Labs Ltd?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Samsrita Labs Ltd is ₹28.51 Cr. as of 22 Nov ‘24
What is the PE and PB ratio of Samsrita Labs Ltd?
The PE and PB ratios of Samsrita Labs Ltd is 0 and 2.33 as of 22 Nov ‘24
What is the 52 Week High and Low of Samsrita Labs Ltd?
The 52-week high/low is the highest and lowest price at which a Samsrita Labs Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Samsrita Labs Ltd is ₹13 and ₹32.36 as of 22 Nov ‘24
What is the CAGR of Samsrita Labs Ltd?
Samsrita Labs Ltd's CAGR for 5 Years at -21.83%, 3 Years at -7.54%, 1 Year at 17.95%, 6 Month at 15.89%, 3 Month at 10.19% and 1 Month at -21.46%.
What is the shareholding pattern of Samsrita Labs Ltd?
The shareholding pattern of Samsrita Labs Ltd is as follows:
Promoters - 52.87 %
Institutions - 0.00 %
Public - 47.13 %
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2024, IIFL Capital Services Ltd. All Rights Reserved
IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
Invest wise with Expert advice
